	US 12,070,501 B1
	Topical ophthalmological compositions
Jinsong Ni, Irvine, CA (US); Van Dinh, Irvine, CA (US); and Rong Yang, Irvine, CA (US)
Assigned to ADS Therapeutics LLC, Irvine, CA (US)
Filed by ADS Therapeutics LLC, Irvine, CA (US)
Filed on Oct. 28, 2022, as Appl. No. 17/976,660.
Application 17/976,660 is a continuation of application No. PCT/US2022/014811, filed on Feb. 2, 2022.
Claims priority of provisional application 63/145,091, filed on Feb. 3, 2021.
Int. Cl. A01N 43/00 (2006.01); A01N 43/46 (2006.01); A61K 9/00 (2006.01); A61K 31/46 (2006.01); A61K 31/55 (2006.01); A61K 47/06 (2006.01); A61K 47/14 (2017.01); A61P 27/10 (2006.01)

CPC A61K 47/14 (2013.01) [A61K 9/0048 (2013.01); A61K 31/46 (2013.01); A61K 47/06 (2013.01); A61P 27/10 (2018.01)]

15 Claims

1. A topical ophthalmological composition comprising:

about 0.001% to about 0.1% (w/w) atropine as an active pharmaceutical ingredient (API);

a medium chain triglyceride (MCT) liquid vehicle; and

a semi-fluorinated alkane compound selected from the group consisting of perfluorobutylheptane (F4H5), perfluorobutylhexane (F4H6), perfluorohexylbutane (F6H4), perfluorohexylhexane (F6H6), perfluorohexyloctane (F6H8), and perfluorohexyl decane (F6H10), wherein the topical ophthalmological composition is non-aqueous.